Charles River to acquire Frontage's bioanalysis and DMPK operations for $470M cash
FROM THE WIRE · SEEKINGALPHA.COM
Charles River to acquire Frontage bioanalysis and DMPK operations for $470M, expanding clinical testing capabilities.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralA mid-sized cash acquisition that expands Charles River's clinical testing capabilities.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Charles River will acquire Frontage's bioanalysis and DMPK operations.
- 02The consideration is $470 million in cash.
- 03The deal expands clinical testing capabilities.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets